Evidence map›Paper›PMID 39602676›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2025

Broad Analysis of Serum and Intrathecal Antimicrobial Antibodies in Multiple Sclerosis Underscores Unique Role of Epstein-Barr Virus.

Florence Pache, Carolin Otto, Diana Wilken, Tatjana Lietzow, Katja Steinhagen, Evelin Grage-Griebenow, Patrick Schindler, Moritz Niederschweiberer, Brigitte Wildemann, Sven Jarius and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. EBNA1Neurology(R) neuroimmunology & neuroinflammation · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Florence PacheFrom the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.
Carolin OttoFrom the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.ORCID 0000-0002-9768-5143
Diana WilkenFrom the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.
Tatjana LietzowFrom the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.
Katja SteinhagenFrom the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.
Evelin Grage-GriebenowFrom the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.
Patrick SchindlerFrom the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.ORCID 0000-0002-8846-121X
Moritz NiederschweibererFrom the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.ORCID 0000-0002-0234-1701
Brigitte WildemannFrom the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.ORCID 0000-0002-5389-3338
Sven JariusFrom the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.ORCID 0000-0003-4849-2545
Klemens RuprechtFrom the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.ORCID 0000-0003-1962-6014

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThere is a strong link between Epstein-Barr virus (EBV) and multiple sclerosis (MS), but the underlying mechanisms are unclear. Patients with MS typically have a polyspecific intrathecal production of immunoglobulin G (IgG), part of which is directed against various microbial antigens. In this study, we comprehensively analyzed seroprevalences and frequencies of an intrathecal IgG production to EBV compared with 10 other common microbes in patients with MS.

methodsAntibodies to EBV and to

resultsWhile 50 (100%) of 50 patients with MS were EBV seropositive, seroprevalences of all other 10 microbes were lower, ranging from 94% (VZV) to 6% ( DISCUSSION: Despite the universal EBV seroprevalence, the frequency of intrathecally produced EBV antibodies in patients with MS is lower than that of other microbes, whose seroprevalences are lower than those of EBV. This seemingly paradoxical finding underscores the unique role of EBV in MS and could be explained by the hypothesis that B lineage cells responsible for intrathecal antibody production are primed during and through acute EBV infection to enter the CNS of patients with MS, that is, at a time point when EBV antibody-producing cells have not yet been generated and, therefore, are not yet available for entering the CNS.

Indexed as

Antibodies, ViralHerpesvirus 4, HumanMultiple SclerosisAdultAgedEpstein-Barr Virus InfectionsFemaleHumansImmunoglobulin GMaleMiddle AgedSeroepidemiologic StudiesYoung AdultAntibodies, ViralImmunoglobulin G

Identifiers

PMID39602676
PMCPMC11616972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.